AbbVie director Quaggin acquires 59 stock-linked units
The units are credited to an unfunded director-fee account and earn the same return as if the fees were invested in AbbVie stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AbbVie Inc. director Susan E. Quaggin acquired 59 Stock Equivalent Units on September 30, 2026, at a reported price of $261.59 per share. Her reported balance after the transaction was 918 Stock Equivalent Units, including units acquired through a dividend reinvestment feature. The reported units are held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Equivalent Units F1, F2 | 59 | $261.59 | $15K |
Footnotes (2)
- F1. Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
- F2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Key Figures
Key Terms
Stock Equivalent Units financial
unfunded book account financial
dividend reinvestment feature financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AbbVie stock equivalent units did Susan E. Quaggin acquire?
AI-generated analysis. How Rhea-AI works. Not financial advice.